Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness.

The widespread presence of autoantibodies in acute infection with SARS-CoV-2 is increasingly recognized, but the prevalence of autoantibodies in non-SARS-CoV-2 infections and critical illness has not yet been reported. We profiled IgG autoantibodies in 267 patients from 5 independent cohorts with non-SARS-CoV-2 viral, bacterial, and noninfectious critical illness. Serum samples were screened using Luminex arrays that included 58 cytokines and 55 autoantigens, many of which are associated with connective tissue diseases (CTDs).

Single-cell RNA sequencing uncovers the nuclear decoy lincRNA PIRAT as a regulator of systemic monocyte immunity during COVID-19.

The systemic immune response to viral infection is shaped by master transcription factors, such as NF-κB, STAT1, or PU.1. Although long noncoding RNAs (lncRNAs) have been suggested as important regulators of transcription factor activity, their contributions to the systemic immunopathologies observed during SARS-CoV-2 infection have remained unknown.

Is the maximal lactate steady state concept really relevant to predict endurance performance?

Purpose: There is no convincing evidence for the idea that a high power output at the maximal lactate steady state (PO) and a high fraction of [Formula: see text]O at MLSS (%[Formula: see text]O) are decisive for endurance performance. We tested the hypotheses that (1) %[Formula: see text]O is positively correlated with the ability to sustain a high fraction of [Formula: see text]O for a given competition duration (%[Formula: see text]O); (2) %[Formula: see text]O improves the prediction of the average power output of a time trial (PO) in addition to [Formula: see text]O and gross efficiency (GE); (3) PO improves the prediction of PO in addition to [Formula: see text]O and GE.

Methods: Twenty-one recreationally active participants performed stepwise incremental tests on the first and final testing day to measure GE and check for potential test-related training effects in terms of changes in the minimal lactate equivalent power output (∆PO_LEmin), 30-min constant load tests to determine MLSS, a ramp test and verification bout for [Formula: see text]O, and 20-min time trials for %[Formula: see text]O and PO.

Autoantibodies targeting cytokines and connective tissue disease autoantigens are common in acute non-SARS-CoV-2 infections.

The widespread presence of autoantibodies in acute infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is increasingly recognized, but the prevalence of autoantibodies in infections with organisms other than SARS-CoV-2 has not yet been reported. We used protein arrays to profile IgG autoantibodies from 317 samples from 268 patients across a spectrum of non-SARS-CoV-2 infections, many of whom were critically ill with pneumonia. Anti-cytokine antibodies (ACA) were identified in > 50% of patients infected with non-SARS-CoV-2 viruses and other pathogens, including patients with pneumonia attributed to bacterial causes.

New-onset IgG autoantibodies in hospitalized patients with COVID-19.

COVID-19 is associated with a wide range of clinical manifestations, including autoimmune features and autoantibody production. Here we develop three protein arrays to measure IgG autoantibodies associated with connective tissue diseases, anti-cytokine antibodies, and anti-viral antibody responses in serum from 147 hospitalized COVID-19 patients. Autoantibodies are identified in approximately 50% of patients but in less than 15% of healthy controls.